Antiangiogenic activity of the cleaved conformation of the serpin antithrombin

Science

Volumn 285, Issue 5435, 1999, Pages 1926-1928

  O'Reilly, Michael S ^a,c   Pirie Shepherd, Steven ^a   Lane, William S ^b   Folkman, Judah ^a  

^a Children's Hospital   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; SERINE PROTEINASE INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FIBRINOLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTITHROMBINS; CARCINOMA, SMALL CELL; CELL LINE; CULTURE MEDIA, CONDITIONED; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0033578910     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.285.5435.1926     Document Type: Article

References (30)

1. F. Rastinejad, P. J. Polverini, N. P. Bouck, Cell 56, 345 (1989).
2. D. Hanahan and J. Folkman, ibid. 86, 353 (1996).
3. M. S. O'Reilly et al., ibid. 79, 315 (1994).
4. M. S. O'Reilly et al., ibid. 88, 277 (1997).
5. 2O and 0.1% trifluoroacetic acid (TFA). Bound protein was eluted with a gradient of acetonitrile in TFA, and a portion of each fraction was evaporated by vacuum centrifugation, resuspended in PBS, and applied to capillary endothelial cells. The inhibitory activity was purified to apparent homogeneity by subsequent cycles on the C4 column.
6. D. L. Evans, C. J. Marshall, P. B. Christey, R. W. Carrell, Biochemistry 31, 12629 (1992).
7. L. Mourey et al., J. Mol Biol. 232, 223 (1993).
8. M. S. O'Reilly, S. Pine-Shepherd, W. S. Lane, J. Folkman, data not shown.
9. J. A. Huntington and P. G. W. Gettins, Biochemistry 37, 3272 (1998).
10. L. Mourey et al., Biochimie 72, 599 (1990).
11. C. W. Pratt and F. C. Church, Semin. Hematol. 28, 3 (1991).
12. H. A. Schreuder et al., Nature Struct. Biol. 1, 48 (1994).
13. R. W. Carrell, D. L. Evans, P. E. Stein, Nature 353, 576 (1991).
14. M. R. Wardell et al., Biochemistry 36, 13133 (1997).
15. Bovine calf serum was stored at 4°C for 14 days to allow for degradation of antithrombin to its R form. Alternatively, outdated human plasma was centrifuged (10,000 rpm for 30 min) and filtered (0.45 μm). Serum or plasma was diluted 1:3 with 10 mM tris-HCl (pH 7.0) and applied to a CM Sepharose column coupled to a DEAE Sepharose column equilibrated with the dilution buffer. The DEAE column was washed with 50 mM NaCl in 10 mM tris-HCl and then coupled to a heparin Sepharose column. Bound protein from the DEAE column was eluted directly onto the heparin Sepharose column with 0.2 M NaCl and 10 mM tris-HCl. The heparin Sepharose column was washed with 0.5 M NaCl and 10 mM tris-HCl and then eluted with a continuous gradient of 0.6 to 2 M NaCl in 10 mM tris-HCl. The purity of the final samples was assessed by SDS-polyacrylamide gel electrophoresis (PAGE) with silver staining, and concentration was determined with a Bio-Rad protein assay.
16. Stressed bovine and human antithrombin were obtained from Sigma or Calbiochem, respectively, or purified as described. Recombinant human antithrombin was obtained as a generous gift from a joint venture between Genryme and Genzyme Transgenics Corporations. Stressed human antithrombin was cleaved by incubation with porcine pancreatic elastase (Calbiochem) for 12 hours at 37°C in PBS (pH 7.8) at a 1:50 molar ratio. Cleaved and latent antithrombin were purified with heparin Sepharose and eluted at 0.4 M NaCl as a distinct peak. Purity was assessed by SDS-PAGE, and samples were concentrated with a Nanospin 30K centrifugal concentrator or lyophilized after dialysis.
17. J. Folkman, in Important Advances in Oncology 1985, S. H. Vincent, T. DeVita, S. Rosenberg, Eds. (Lippincott, Philadelphia, PA. 1985), pp. 42-62.
18. M. S. O'Reilly, L. Holmgren, C. C. Chen, J. Folkman, Nature Med. 2, 689 (1996).
19. T. Boehm, J. Folkman, T. Browder, M. S. O'Reilly, Nature 390, 404 (1997).
20. K. Akiyama et al., Thromb. Res. 72, 193 (1993).
21. L. R. Zacharski, Onkologie 10, 264 (1987).
22. _, V. A. Memoli, S. M. Rousseau, W. Kisiel, Cancer 60, 2675 (1987).
23. H. F. Dvorak, N. Engl. J. Med. 315, 1650 (1986).
24. _, J. A. Nagy, J. T. Dvorak, A. M. Dvorak, Am. J. Pathol. 133, 95 (1988).
25. S. S. Tolsma et al., J. Cell Biol. 122, 497 (1993).
26. T. E. Maione et al., Science 247, 77 (1990).
27. S. K. Gupta, T. Hassel, J. P. Singh, Proc. Natl. Acad. Sci. U.S.A. 92, 7799 (1995).
28. R. W. Colman, Y. Lin, D. Johnson, S. A. Mousa, Blood 92(suppl.), 174a (1998).
29. T. Lee, Y. Rhim, S. S. Kim, J. Biol. Chem. 273, 28805 (1998).
30. We thank J. M. Neveu for Edman microsequencing, the staff of the blood bank of Children's Hospital for providing the outdated plasma, Genzyme and Genzyme Trangenics Corporations for recombinant human antithrombin, L. DeSantis and K. Gullage for photography, E. Flynn for immunohistochemistry, and Advanced Medical Graphics for help with the figures. Supported in part by NIH grants RO1-CA64481 and PO1-CA45548.